✦ LIBER ✦

2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)

✍ Scribed by T. Pienkowski; M. Pegram; J. Forbes; V. Valero; W. Eiermann; G. Von Minckwitz; M. Martin; J. Crown

Book ID: 118625702
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 77 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(07)70860-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase III trial of trastuzuma

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

Randomized Phase III Placebo-Controlled

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

✍ Wolff, A. C.; Lazar, A. A.; Bondarenko, I.; Garin, A. M.; Brincat, S.; Chow, L.; 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 194 KB